<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Response-Depth–Tailored Duration-Value Theory - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-30</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-30</p>
                <p><strong>Name:</strong> Response-Depth–Tailored Duration-Value Theory</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of the optimal duration of anti-PD-1 immunotherapy for melanoma, and whether it differs by depth of response, based on the following results.</p>
                <p><strong>Description:</strong> The optimal anti-PD-1 duration in metastatic melanoma is a function of response depth and biomarker conversion, balancing marginal disease-control gains against cumulative toxicity and cost. CR generally requires 6–12 months total exposure; PR can stop at ~12 months if PET/ctDNA-converted, otherwise benefit accrues to ~18–24 months; SD rarely meets safe-stop criteria before 24 months without biomarker conversion. Beyond ~24 months, incremental benefit is small relative to rising late irAEs and cost.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>A PR cohort selected by PET CMR and ctDNA negativity at ~12 months will have noninferior 24-month off-therapy PFS compared with CR stoppers (difference ≤5% absolute).</li>
                <li>SD patients who achieve PET CMR and ctDNA negativity between 12–24 months will have ≥70% 24-month off-therapy PFS; those without conversion will have ≤50%.</li>
                <li>Stopping at 24 months among PET/ctDNA-converted PR/SD will not reduce 3-year OS versus continuing, but will reduce late irAE incidence by ≥15% absolute.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>A minority of PET CMR, ctDNA-negative SD at 12 months can safely stop with close surveillance, especially if baseline tumor metabolic volume was low.</li>
                <li>ctDNA clearance kinetics (half-life/time-to-undetectable) will refine the duration windows and predict need for 18 vs 24 months in PR.</li>
                <li>Granzyme-B PET could substitute for FDG-PET in inflamed lesions to better discriminate true residual disease, enabling earlier safe stopping.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If PET/ctDNA-selected PRs stopping at 12 months show >20% 24-month relapse, early stop is too permissive for PR and window must shift later.</li>
                <li>If continuing beyond 24 months post-conversion reduces 3-year OS by >5% absolute (i.e., harms accrue from stopping), the cap needs reevaluation.</li>
                <li>If SD patients with PET/ctDNA conversion still relapse >30% by 24 months off therapy, SD may require alternative strategies rather than duration alone.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Economic endpoints (ICER/QALYs) are not quantified here but are planned in DANTE and STOP-GAP; actual cost-effectiveness thresholds may refine duration windows. <a href="../results/extraction-result-87.html#e87.11" class="evidence-link">[e87.11]</a> <a href="../results/extraction-result-87.html#e87.6" class="evidence-link">[e87.6]</a> <a href="../results/extraction-result-85.html#e85.4" class="evidence-link">[e85.4]</a> <a href="../results/extraction-result-87.html#e87.8" class="evidence-link">[e87.8]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>